Cancer therapies have advanced tremendously throughout the last decade, yet multiple
factors still hinder the success of the different cancer therapeutics. The traditional therapeutic …

Immunotherapy has gradually emerged as the most promising anticancer therapy. In
addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc …

A remaining challenge in the treatment of glioblastoma multiforme (GBM) is surmounting the
blood–brain barrier (BBB). Such a challenge prevents the development of efficient …

The limited drug penetration and robust bacteria‐mediated drug inactivation in pancreatic
cancer result in the failure of chemotherapy. To fight against these issues, a dual‐cascade …

Orally administrable anticancer nanomedicines are highly desirable due to their easy and
repeatable administration, but are not yet feasible because the current nanomedicine cannot …

Glioblastoma (GBM) is among the most treatment-resistant solid tumors and often recurrs
after resection. One of the mechanisms through which GBM escapes various treatment …

Immunotherapy has delivered impressive outcomes in combating tumor malignancies.
However, insufficient immune infiltration and poor immunogenicity within the tumor …

Diffuse intrinsic pontine glioma (DIPG) is a rare and fatal pediatric brain tumor. Mutation of
p53‐induced protein phosphatase 1 (PPM1D) in DIPG cells promotes tumor cell …

Thrombotic cerebro-cardiovascular diseases are the leading causes of disability and death
worldwide. However, current drug therapeutics are compromised by narrow therapeutic …

Glioblastoma (GBM) is a highly fatal and recurrent brain cancer without a complete
prevailing remedy. Although the synthetic nanotechnology-based approaches exhibit …